Commentary
See article on page 553LKM antibody: getting in some target practice
| The first 150 words of the full text of this article appear below. |
In the current issue of the journal (see page 553), Muratori et al provide convincing evidence that cytochrome P4502D6 (CYP2D6) is present on the liver cell plasma membrane. This finding has important implications because CYP2D6 is the main target of liver kidney microsomal antibody type 1 (LKM1). Not only is LKM1 the serological hallmark of autoimmune hepatitis type 2 but it is also found in up to 10% of patients with chronic hepatitis C virus (HCV) infection where it appears to single out patients experiencing serious side effects while receiving interferon treatment.1
The issue as to whether CYP2D6 is present on the plasma membrane was
critically reviewed in 19932 but was not resolved in view
of the contrasting evidence at the time. Muratori
et al have settled this matter by incubating
LKM1 containing sera with live hepatocytes which can offer the external
aspect of the plasma membrane to the antibody. The
Relevant Article
- Liver/kidney microsomal antibody type 1 targets CYP2D6 on hepatocyte plasma membrane
- L Muratori, M Parola, A Ripalti, G Robino, P Muratori, G Bellomo, R Carini, M Lenzi, M P Landini, E Albano, and F B Bianchi
Gut 2000 46: 553-561.[Abstract] [Full Text] [PDF]
Register for free content
The full back archive is now available for all BMJ Journals. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006 right back to volume 1 issue 1. Register here to access the free archive of all BMJ Journals.
Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.
